Literature DB >> 33432180

The emerging role of checkpoint inhibitors for rare genitourinary cancers.

Jeanny B Aragon-Ching1.   

Abstract

Entities:  

Year:  2021        PMID： 33432180     DOI： 10.1038/s41585-021-00426-8

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.

Authors:  Bradley Alexander McGregor; Matthew T Campbell; Wanling Xie; Subrina Farah; Mehmet A Bilen; Andrew L Schmidt; Guru P Sonpavde; Kerry L Kilbridge; Atish D Choudhury; Amir Mortazavi; Amishi Y Shah; Aradhana M Venkatesan; Glenn J Bubley; Arlene O Siefker-Radtke; Rana R McKay; Toni K Choueiri
Journal:  Cancer       Date:  2020-11-20       Impact factor: 6.860

Review 2.  Targetable gene fusions and aberrations in genitourinary oncology.

Authors:  Filippo Pederzoli; Marco Bandini; Laura Marandino; Siraj M Ali; Russell Madison; Jon Chung; Jeffrey S Ross; Andrea Necchi
Journal:  Nat Rev Urol       Date:  2020-10-12       Impact factor: 14.432
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.